Latham & Watkins Advises GRAIL in Spin-Off From Illumina and Nasdaq Launch

GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, has announced its spin-off from Illumina (NASDAQ: ILMN) is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of June 25, 2024.

Latham & Watkins advised GRAIL in the transaction with a corporate deal team led by Los Angeles/Century City partner Alex Voxman, Century City partner Andrew Clark, Orange County/Bay Area partner Ross McAloon, Chicago partner Alexa Berlin, and Century City counsel Alexandra McArthur, with associates KC Sands, Raul Gonzalez, Natalie Robertson, Tim Plummer, and Diana Chung. Advice was also provided on executive compensation and employee benefits matters by Los Angeles partner Larry Seymour, with associate Megan Ampe; on tax matters by Century City/Los Angeles partner Pardis Zomorodi and Century City counsel Will Kessler; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards and Washington, D.C. counsel Chad Jennings; on healthcare regulatory matters by Bay Area partner Betty Pang and Paris partner Eveline Van Keymeulen; on data privacy matters by Bay Area partner Heather Deixler; on IP matters by San Diego partner Chris Hazuka and Los Angeles partner Ghaith Mahmood, with associates Robert Yeh, Kristina Funahashi, Nicole Nour, and Patrick Chew; on insurance matters by San Diego partner Drew Gardiner, with associate John Niemeyer; on US antitrust matters by Washington, D.C. partners Michael Egge, Maggy Sullivan, and Anna Rathbun, and Bay Area partner Al Pfeiffer; and on EU antitrust matters by Brussels partners David Little, Javier Ruiz-Calzado, and Carles Esteva Mosso, Madrid partner José María Jiménez-Laiglesia, and Paris partner Adrien Giraud, with associates Anna Escrigas Cañameras, Daniel Muheme, and Simon Troch.